Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
51.89
+0.06 (0.12%)
After Hours: 51.89 0.00 (0.00%)
Mar 28, 5:00PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 51.57 - 51.99
52 week 39.98 - 52.33
Open 51.75
Vol / Avg. 2.37M/2.86M
Mkt cap 28.02B
P/E 5.77
Div/yield 0.13/1.00
EPS 9.00
Shares 541.96M
Beta 0.79
Inst. own 87%
Jan 31, 2017
Q4 2016 Baxter International Inc Earnings Release (Estimated)
Jan 9, 2017
Baxter International Inc at JPMorgan Healthcare Conference- Q&A Session
Jan 9, 2017
Baxter International Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 9.07% 48.86%
Operating margin 10.81% 5.66%
EBITD margin - 16.65%
Return on average assets 6.14% 27.20%
Return on average equity 11.35% 57.96%
Employees 48,000 -
CDP Score - 99 B

Address

One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 53
Bio & Compensation  - Reuters
Scott Pleau Corporate Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Sean Martin Corporate Vice President, General Counsel
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Giuseppe Accogli Corporate Vice President and President - Renal
Age: 46
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 53
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters